These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 922743)

  • 41. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
    Ling YH; Priebe W; Perez-Soler R
    Cancer Res; 1993 Apr; 53(8):1845-52. PubMed ID: 8467504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
    Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
    Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cross-resistance to rhodamine 123 in Adriamycin- and daunorubicin-resistant Friend leukemia cell variants.
    Tapiero H; Munck JN; Fourcade A; Lampidis TJ
    Cancer Res; 1984 Dec; 44(12 Pt 1):5544-9. PubMed ID: 6498816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
    Harker WG; Sikic BI
    Cancer Res; 1985 Sep; 45(9):4091-6. PubMed ID: 4028002
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characteristics of uptake and cytotoxicity of a low-density lipoprotein-daunomycin complex in P388 leukemic cells.
    Yanovich S; Preston L; Shaw JM
    Cancer Res; 1984 Aug; 44(8):3377-82. PubMed ID: 6744272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isolation and characterization of an anthracycline-resistant human leukemic cell line.
    Bhalla K; Hindenburg A; Taub RN; Grant S
    Cancer Res; 1985 Aug; 45(8):3657-62. PubMed ID: 3860286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
    Inaba M; Nagashima K
    Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Sensitivity to chemotherapeutic preparations of anthracycline-resistant strains of murine leukemia P388].
    Demidova NS; Goncharova SA; Shiriaeva OA; Konovalova NP
    Eksp Onkol; 1989; 11(1):65-8. PubMed ID: 2924713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased phorbol ester receptor and protein kinase C in P388 murine leukemic cells resistant to etoposide.
    Ido M; Sato K; Sakurai M; Inagaki M; Saitoh M; Watanabe M; Hidaka H
    Cancer Res; 1987 Jul; 47(13):3460-3. PubMed ID: 3581082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
    Hait WN; Pierson NR
    Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells.
    Ramu A; Cohen L; Glaubiger D
    Cancer Res; 1984 May; 44(5):1976-80. PubMed ID: 6324993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells.
    Ramu A; Shan TC; Glaubiger D
    Cancer Treat Rep; 1983 Oct; 67(10):895-9. PubMed ID: 6354437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
    Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of adriamycin on the reverse transcriptase and the production of murine leukemia virus.
    Tomita Y; Kuwata T
    Cancer Res; 1976 Sep; 36(9 pt.1):3016-9. PubMed ID: 61807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cross-resistance of vincristine-resistant sublines of P388 leukemia to mitoxantrone with special emphasis on the relationship between in vitro and in vivo cross-resistance.
    Inaba M; Nagashima K; Sakurai Y
    Gan; 1984 Jul; 75(7):625-30. PubMed ID: 6468847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanism of natural resistance to vincristine in rat ascites hepatoma AH66.
    Inaba M; Takayama K; Sakurai Y
    Gan; 1981 Aug; 72(4):562-8. PubMed ID: 7308668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biochemical parameters of resistance of an adriamycin-resistant subline of P388 leukemia to emetine, an inhibitor of protein synthesis.
    Chitnis MP; Johnson RK
    J Natl Cancer Inst; 1978 May; 60(5):1049-54. PubMed ID: 642026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.